Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG115

—

55632103-e71e-503a-afd4-d2369ce241d5

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TNFA_SIGNALING_VIA_NFKB+0.555
  • ESTROGEN_RESPONSE_EARLY+0.456
  • TGF_BETA_SIGNALING+0.456
  • ANGIOGENESIS+0.415
  • CHOLESTEROL_HOMEOSTASIS+0.400
  • APICAL_JUNCTION+0.391
  • ESTROGEN_RESPONSE_LATE+0.390
  • HYPOXIA+0.390
  • HEDGEHOG_SIGNALING+0.380
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.368

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.497
  • MYC_TARGETS_V1-0.442
  • MYC_TARGETS_V2-0.411
  • INTERFERON_ALPHA_RESPONSE-0.379
  • DNA_REPAIR-0.347
  • E2F_TARGETS-0.341
  • G2M_CHECKPOINT-0.217
  • PROTEIN_SECRETION-0.160
  • INTERFERON_GAMMA_RESPONSE-0.155
  • ALLOGRAFT_REJECTION-0.154

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG119
mng-umap@100
——0.975
2TCGA-22-4605-01A-21R-2125-07
lung-landscapes@6
—cohortSQ10.895
320030015.LumB
breast-umap@18
—A0.874
4TCGA-OL-A6VQ-01A-12R-A41B-07
breast-umap@18
—A0.869
54c7083b3-eccc-4d80-a31d-6fd3cd0222b4
colon-landscapes@1
——0.869
6SRR15069612
head-neck@1
——0.861
76b548699-9440-4acc-86b6-faeb367454a2
colon-landscapes@1
——0.861
8TCGA-E2-A153-01A-12R-A12D-07
breast-umap@18
—A0.859
9MNG828
mng-umap@100
——0.857
10TCGA-CV-5970-01A-11R-1686-07
head-neck@1
——0.856

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 33 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TNFA_SIGNALING_VIA_NFKB0.555Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.456Inavolisib— uncovered
TGF_BETA_SIGNALING0.456Inavolisib— uncovered
ANGIOGENESIS0.415Remibrutinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.400Remibrutinib— uncovered
APICAL_JUNCTION0.391Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.390Idelalisib— uncovered
HYPOXIA0.390Idelalisib— uncovered
HEDGEHOG_SIGNALING0.380Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.368Inavolisib— uncovered
COAGULATION0.347Binimetinib— uncovered
UV_RESPONSE_DN0.338Inavolisib— uncovered
APICAL_SURFACE0.323Temsirolimus— uncovered
MYOGENESIS0.306Inavolisib— uncovered
IL2_STAT5_SIGNALING0.275Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.267Idelalisib— uncovered
APOPTOSIS0.262Idelalisib— uncovered
KRAS_SIGNALING_DN0.253Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.251Inavolisib— uncovered
KRAS_SIGNALING_UP0.244Inavolisib— uncovered